Holdings
Invesco Biotechnology & Genome ETF
As of Jul 31, 2026, Invesco Biotechnology & Genome ETF reported 29 positions worth US$278M. Largest: Regeneron Pharmaceuticals, Inc., Amgen Inc. and Caredx, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 20,233 | US$15.4M | +3,549 | Jul 31, 2026 |
| Amgen Inc. | 38,223 | US$14.7M | +4,572 | Jul 31, 2026 |
| Caredx, Inc. | 325K | US$14.2M | −39,886 | Jul 31, 2026 |
| Vertex Pharmaceuticals Incorporated | 29,460 | US$14.1M | new | Jul 31, 2026 |
| Royalty Pharma Plc | 238K | US$13.9M | +83,631 | Jul 31, 2026 |
| Biogen Inc. | 66,507 | US$13.5M | +482 | Jul 31, 2026 |
| Gilead Sciences, Inc. | 96,026 | US$12.5M | +8,762 | Jul 31, 2026 |
| United Therapeutics Corporation | 22,197 | US$11.5M | −5,015 | Jul 31, 2026 |
| Bio-techne Corp | 146K | US$10.5M | +24,015 | Jul 31, 2026 |
| Illumina, Inc. | 48,231 | US$9.89M | −56,601 | Jul 31, 2026 |